{
    "nctId": "NCT02150525",
    "briefTitle": "Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors",
    "officialTitle": "A Randomized Trial to Explore the Effect of Oral Omega 3 Fatty Acids on Atrophic Vaginitis in Postmenopausal Breast Cancer Survivors",
    "overallStatus": "COMPLETED",
    "conditions": "Ductal Breast Carcinoma in Situ, Breast Cancer, Stage I, Breast Cancer, Stage II, Breast Cancer, Stage III",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 52,
    "primaryOutcomeMeasure": "Explore the ability of oral omega 3 fatty acids to improve symptoms of atrophic vaginitis as self-reported by postmenopausal breast cancer survivors that took omega 3 vs. those survivors who did not take omega 3.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Woman with a history of breast cancer, stage 0, I, II, or III\n* At least 12 months from definitive surgical procedure (i.e. lumpectomy or mastectomy)\n* At least 3 months from completion of chemotherapy\n* Postmenopausal, defined as no menstrual cycle for 12 consecutive months, or surgical menopause\n* Have one or more stated symptoms of atrophic vaginitis, such as vaginal dryness, genital irritation/itching, genital pain, and/or dyspareunia\n* No current use of estrogen replacement therapy\n* If recent use of estrogen replacement therapy, off at least three months\n* No current use of estradiol-releasing vaginal ring or estradiol vaginal tablets; if recent use of these products, off at least 3 consecutive months\n* No evidence of disease (NED), any cancer other than breast cancer\n* No current use of oral omega 3 fatty acids or Vitamin E; if recent consistent use of these products, off at least six months; if sporadic use of these products, off at least 3 consecutive months\n* May be taking oral anti-estrogens or aromatase inhibitors, and/or biologic therapy\n* Must be willing to undergo venipuncture at 0, 3, and 6 months\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* No history of a bleeding tendency\n* No history of uncontrolled hypertension, heart disease or stroke\n* Hemoglobin \\> 10 g/dL\n* Hematocrit \\> 30%\n* White blood count \\> 3.5 K/uL\n* Platelet count \\> 100,000/mm\\^3\n* Fasting serum glucose \\< 115 mg/dL\n* Total bilirubin \\< 1.6 mg/dL\n* Transaminases alanine aminotransferase(ALT)and aspartate aminotransferase (AST)\\< 1.5 x ULN (upper limit of normal)\n\nExclusion Criteria:\n\n* Metastatic malignancy of any kind\n* Ongoing chemotherapy or radiation therapy (ongoing hormonal therapy and/or biologic therapy are allowed)\n* History of pelvic or genital radiation therapy\n* Use of Coumadin or other anticoagulants\n* Known, active pelvic, vaginal, or urinary tract infections\n* Current use of hormone replacement therapy, either systemic or local\n* Uncontrolled co-morbidities including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, unstable hypertension\n* Psychiatric illness/social situation that would limit adherence to study requirements\n* Consistent use of omega-3 fatty acid concentrates or capsules within the 6 months prior to entry on the study\n* Known sensitivity or allergy to fish oil or omega 3 fish products\n* Pregnant or nursing women\n* Subjects who cannot give an informed consent",
    "sex": "FEMALE",
    "minimumAge": "45 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}